Connect Biopharma, Ickey Woods Foundation collaborate on asthma education.

Connect Biopharma and the Jovante Woods Foundation collaborate to raise asthma awareness and education. The partnership aims to expand the foundation's asthma education program across the U.S. The foundation was established by former Cincinnati Bengals running back Elbert "Ickey" Woods after his son Jovante died from an acute asthma attack in 2010. The collaboration focuses on driving asthma education and raising awareness of the need for new treatments.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) has announced a collaboration with the Jovante Woods Foundation to expand its asthma education program across the United States. The partnership aims to raise awareness about asthma, particularly acute attacks, and highlight the need for new treatments.

The Jovante Woods Foundation was established by former Cincinnati Bengals running back Elbert "Ickey" Woods following the loss of his 16-year-old son, Jovante, to an acute asthma attack in 2010. Since its inception, the foundation has hosted educational events and fundraisers in Ohio, California, and Nevada, all areas with personal ties to Woods. With the support of Connect Biopharma, the foundation plans to bring community events to even more markets throughout the upcoming NFL season.

Connect Biopharma, a clinical-stage biopharmaceutical company, is dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is developing rademikibart, a next-generation antibody targeting interleukin-4 receptor alpha (IL-4Rα), which could potentially treat Th2-related inflammatory diseases such as asthma. The collaboration aligns with Connect's ongoing work to develop rademikibart as a treatment for acute asthma exacerbations.

The partnership involves a social media campaign and the production of a video package sharing Jovante's story and educational information about asthma attacks and treatments. Barry Quart, CEO of Connect Biopharma, noted that the partnership is crucial for preventing asthma deaths and addressing the need for new treatments for acute asthma exacerbations. The company is currently recruiting patients for phase 2 studies of rademikibart, with a top-line data readout expected in the first half of next year.

The Centers for Disease Control and Prevention reports that more than 3,500 people in the U.S. die from asthma each year. According to the foundation, approximately 50% of individuals who experience an acute attack will have another exacerbation within four weeks, highlighting the importance of education and awareness.

This collaboration underscores Connect Biopharma's commitment to improving asthma treatment and supporting initiatives that raise awareness about the disease. The expanded education program aims to reach more families and communities, potentially preventing asthma-related deaths and improving the lives of those affected by the condition.

References:
[1] https://www.fiercepharma.com/marketing/connect-biopharma-joins-nfl-star-ickey-woods-asthma-education-blitz
[2] https://www.morningstar.com/news/globe-newswire/9511339/connect-biopharma-teams-with-ickey-woods-and-the-jovante-woods-foundation-to-expand-asthma-education-program-nationwide